Michael Smolinski

Michael Smolinski has extensive work experience in the field of pharmaceuticals and drug development. Michael currently holds the position of Vice President of Development and Scientific Operations at Veradermics, where they have been since July 2023. Prior to this, they founded and served as the Principal of Chemia Consulting LLC starting from March 2023.

From 2018 to 2023, Smolinski worked as an Entrepreneur in Residence at the University at Buffalo. During this time, they also volunteered for the University at Buffalo Center for Advanced Technology Grant Review Board.

Smolinski has held various important roles at Athenex, starting from 2015. Michael worked as the Senior Advisor, Proprietary Products from May 2022 to May 2023. Before this, they served as the Chief Scientific Officer, Vice President of Preclinical Operations, Senior Director of Preclinical Operations, Director of Preclinical Operations, and Associate Director of Preclinical Operations, where they were responsible for drug development and CMC documentation.

In 2022, Smolinski briefly worked as the Sr. VP Chemical Development and Pharmaceutical Sciences at Nirogy Therapeutics. Michael was also associated with Kinex Pharmaceuticals from 2008 to 2015, where they held the positions of Associate Director of Preclinical Operations, Assistant Director of Chemistry, and Senior Research Chemist. At Kinex Pharmaceuticals, they played a vital role in building a chemistry lab and developing a photoaffinity-based technological platform for identifying protein targets.

Additionally, Smolinski has volunteered as a mentor and resource for graduate students at the University at Buffalo Chemistry Department from 2011 to 2013. Michael began their research career as a Research Associate at Scripps Florida from 2006 to 2007, focusing on target-based drug discovery.

Overall, Michael Smolinski has demonstrated a wealth of experience and expertise in the pharmaceutical industry, encompassing various roles and responsibilities throughout their career.

Michael Smolinski obtained their PhD in Medicinal Chemistry from the University at Buffalo, where they pursued their education from 2001 to 2006.